流行性乙型脑炎病毒单克隆抗体用于临床治疗的初步观察

Preliminary observation on treatment of patients with Japanese B encephalitis by monoclonal antibodies

作者参照美国药品食品管理局制定的“人用McAb制剂生产鉴定细则”,纯化流行性乙型脑炎病毒单克隆抗体混合制剂。以10mg总剂量,1次静脉滴入加肌肉注射治疗乙脑患者55例,作为乙脑单抗组,另设病毒唑组17例、胸腺肽组7例和对症处理组12例,作为对照。4组的平均退热日数分别为2.86,7.16,9.11,6.20d,乙脑单抗组明显少于其他3组,相差显著(P<0.05)或非常显著(P<0.01);4组的痊愈率分别为80.0%,70.6%,42.9%和50%,经统计分析各组间疗效无显著差异(P>0.05),作者在使用McAb前,均先做皮肤过敏试验,使用McAb时并给予地塞米松。

The monoclonal antibodies (McAbs) against Japanese B encephalitis virus for clinical use were prepared according to the standards of food and drug administration (FDA). Immediately after the diagnosis, the patients were given 10 mg of McAbs (IgG) by intravenous drip plus intramuscular injection. The febrifugal days on average of the McAb treatment group, symptomatic treatment group, ribavirin treatment group and thymus peptides treatment group were 2-86, 6-20, 7.16, and 9.11 days, respectively (P<0.05 or P<0.01). It is necessary to take the skin test before use of the McAbs and to give dexamethasone during the McAb treatment.